Prosthetic heart valves: Catering for the few

Biomaterials

Volumn 29, Issue 4, 2008, Pages 385-406

  Zilla, Peter ^a   Brink, Johan ^a   Human, Paul ^a   Bezuidenhout, Deon ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Bioprosthesis; Calcification; Degradation; Heart valve; Immune response; Thrombogenicity

Indexed keywords

CALCIFICATION (BIOCHEMISTRY); CATHETERS; IMMUNOLOGY; PATIENT MONITORING; TISSUE; VALVES (MECHANICAL);

BIOPROSTHESIS; HEART VALVES; IMMUNE RESPONSE; MEDICAL SYSTEMS; THROMBOGENICITY;

PROSTHETICS;

WARFARIN;

ARTICLE; BIOPROSTHESIS; BLEEDING; BRAIN HEMORRHAGE; CALCIFICATION; DEGRADATION; HEART VALVE PROSTHESIS; HUMAN; IMMUNE RESPONSE; NONHUMAN; PANNUS; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; THROMBOGENICITY;

ANIMALS; ANTIGENS; CATHETERIZATION; HEART VALVE PROSTHESIS; HEART VALVES; HUMANS; THROMBOEMBOLISM; TISSUE ENGINEERING;

EID: 36048938374     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2007.09.033     Document Type: Article

References (219)

1. Harken D., Soroff H., Taylor W., Lefemine A., Gupta S., and Lunzer S. Partial and complete prostheses in aortic insufficiency. J Thorac Cardiovasc Surg 40 6 (1960) 744-762
2. Braunwald N.S., Cooper T., and Morrow A.G. Complete replacement of the mitral valve. Successful clinical application of a flexible polyurethane prosthesis. J Thorac Cardiovasc Surg 40 (1960) 1-11
3. O'Brien M., and Clarebrough J. Heterograft aortic valve translantation for valve disease. Med J Aust 2 (1966) 228-232
4. Carpentier A., Lemaigre G., Robert L., Carpentier S., and Dubost C. Biological factors affecting long-term results of valvular heterografts. J Thorac Cardiovasc Surg 58 4 (1969) 467-483
5. Starr A., and Edwards M.L. Mitral replacement: clinical experience with a ball-valve prosthesis. Ann Surg 154 (1961) 726-740
6. Bjork V.O. Aortic valve replacement with the Bjork-Shiley tilting disc valve prosthesis. Br Heart J 33 Suppl (1971) 42-46
7. Emery R.W., Mettler E., and Nicoloff D.M. A new cardiac prosthesis: the St. Jude Medical cardiac valve: in vivo results. Circulation 60 2, Part 2 (1979) 48-54
8. Sacks M. The biomechanical effects of fatigue on the porcine bioprosthetic heart valve. J Long Term Eff Med Implants 11 3 & 4 (2001) 231-247
9. Butany J., and Collins M.J. Analysis of prosthetic cardiac devices: a guide for the practising pathologist. J Clin Pathol 58 2 (2005) 113-124
10. McLaren M.J., Hawkins D.M., Koornhof H.J., Bloom K.R., Bramwell-Jones D.M., Cohen E., et al. Epidemiology of rheumatic heart disease in black shcoolchildren of Soweto, Johannesburg. Br Med J 3 5981 (1975) 474-478
11. Pezzella A.T. International cardiac surgery: a global perspective. Semin Thorac Cardiovasc Surg 14 4 (2002) 298-320
12. Stahle E., Kvidal P., Nystrom S.O., and Bergstrom R. Long-term relative survival after primary heart valve replacement. Eur J Cardiothorac Surg 11 1 (1997) 81-91
13. Antunes M.J., Wessels A., Sadowski R.G., Schutz J.G., Vanderdonck K.M., Oliveira J.M., et al. Medtronic Hall valve replacement in a third-world population group. A review of the performance of 1000 prostheses. J Thorac Cardiovasc Surg 95 6 (1988) 980-993
14. Kinsley R.H., Antunes M.J., and Colsen P.R. St. Jude Medical valve replacement. An evaluation of valve performance. J Thorac Cardiovasc Surg 92 3, Part 1 (1986) 349-360
15. Unger F., and Ghosh P. International cardiac surgery. Semin Thorac Cardiovasc Surg 14 4 (2002) 321-323
16. Grunkemeier G.L., Jamieson W.R., Miller D.C., and Starr A. Actuarial versus actual risk of porcine structural valve deterioration. J Thorac Cardiovasc Surg 108 4 (1994) 709-718
17. Edwards Lifesciences OEW, Irvine, CA 92614-5686, USA. Clinical Communique, Carpentier-Edwards Perimount, Pericardial Bioprosthesis, Model 2700. Edwards Lifesciences LLC.
18. Bodnar E., and Blackstone E.H. An "actual" problem: another issue of apples and oranges. J Thorac Cardiovasc Surg 131 1 (2006) 1-3
19. Blackstone E.H. Could it happen again? The Bjork-Shiley convexo-concave heart valve story. Circulation 111 21 (2005) 2717-2719
20. Wieting D.W., Eberhardt A.C., Reul H., Breznock E.M., Schreck S.G., and Chandler J.G. Strut fracture mechanisms of the Bjork-Shiley convexo-concave heart valve. J Heart Valve Dis 8 2 (1999) 206-217
21. Blot W.J., Ibrahim M.A., Ivey T.D., Acheson D.E., Brookmeyer R., Weyman A., et al. Twenty-five-year experience with the Bjork-Shiley convexoconcave heart valve: a continuing clinical concern. Circulation 111 21 (2005) 2850-2857
22. Mert M., Ozkara A., and Hatemi A. Leaflet escape in a revised Edwards-Duromedics mitral prosthesis. J Heart Valve Dis 12 4 (2003) 513-515
23. Oxman H.A., Connolly D.C., and Ellis Jr. F.H. Mitral valve replacement with the Smeloff-Cutter prosthesis. Experience with 154 patients and comparison with results of replacement with a Starr-Edwards prosthesis. J Thorac Cardiovasc Surg 69 2 (1975) 247-254
24. Mastroroberto P., Chello M., Bevacqua E., Cirillo F., and Covino E. Duromedics original prosthesis: what do we really know about diagnosis and mechanism of leaflet escape?. Can J Cardiol 16 10 (2000) 1269-1272
25. Johansen P. Mechanical heart valve cavitation. Expert Rev Med Devices 1 1 (2004) 95-104
26. Klepetko W., Moritz A., Mlczoch J., Schurawitzki H., Domanig E., and Wolner E. Leaflet fracture in Edwards-Duromedics bileaflet valves. J Thorac Cardiovasc Surg 97 1 (1989) 90-94
27. Walker A.M., Funch D.P., Sulsky S.I., and Dreyer N.A. Manufacturing characteristics associated with strut fracture in Bjork-Shiley 60 degrees convexo-concave heart valves. J Heart Valve Dis 4 6 (1995) 640-648
28. Cohn L.H., Sanders J.H., and Collins Jr. J.J. Actuarial comparison of Hancock porcine and prosthetic disc valves for isolated mitral valve replacement. Circulation 54 6, Suppl (1976) III60-III63
29. DiSesa V.J., Tam S., and Cohn L.H. Ligation of the left atrial appendage using an automatic surgical stapler. Ann Thorac Surg 46 6 (1988) 652-653
30. Chandran K.B., Yearwood T.L., Chen C.J., and Falsetti H.L. Pulsatile flow experiments on heart valve prostheses. Med Biol Eng Comput 21 5 (1983) 529-537
31. Ibrahim M., O'Kane H., Cleland J., Gladstone D., Sarsam M., and Patterson C. The St. Jude Medical prosthesis. A thirteen-year experience. J Thorac Cardiovasc Surg 108 2 (1994) 221-230
32. Beaudet R.L., Poirier N.L., Doyle D., Nakhle G., and Gauvin C. The Medtronic-Hall cardiac valve: 7 1/2 years' clinical experience. Ann Thorac Surg 42 6 (1986) 644-650
33. Hall K.V., Nitter-Hauge S., and Abdelnoor M. Seven and one-half years' experience with the Medtronic-Hall valve. J Am Coll Cardiol 6 6 (1985) 1417-1421
34. Copans H., Lakier J.B., Kinsley R.H., Colsen P.R., Fritz V.U., and Barlow J.B. Thrombosed Bjork-Shiley mitral prostheses. Circulation 61 1 (1980) 169-174
35. Levantino M., Tartarini G., Barzaghi C., Grana M., and Bortolotti U. Survival despite almost complete occlusion by chronic thrombosis of a Bjork-Shiley mitral prosthesis. J Heart Valve Dis 4 1 (1995) 103-105
36. Cobanoglu A., Grunkemeier G.L., Aru G.M., McKinley C.L., and Starr A. Mitral replacement: clinical experience with a ball-valve prosthesis. Twenty-five years later. Ann Surg 202 3 (1985) 376-383
37. Grunkemeier G.L., Li H.H., Naftel D.C., Starr A., and Rahimtoola S.H. Long-term performance of heart valve prostheses. Curr Probl Cardiol 25 2 (2000) 73-154
38. Miller D.C., Oyer P.E., Stinson E.B., Reitz B.A., Jamieson S.W., Baumgartner W.A., et al. Ten to fifteen year reassessment of the performance characteristics of the Starr-Edwards Model 6120 mitral valve prosthesis. J Thorac Cardiovasc Surg 85 1 (1983) 1-20
39. Schoevaerdts J.C., Buche M., el Gariani A., Lichtsteiner M., Jaumin P., Ponlot R., et al. Twenty years' experience with the Model 6120 Starr-Edwards valve in the mitral position. J Thorac Cardiovasc Surg 94 3 (1987) 375-382
40. Godje O.L., Fischlein T., Adelhard K., Nollert G., Klinner W., and Reichart B. Thirty-year results of Starr-Edwards prostheses in the aortic and mitral position. Ann Thorac Surg 63 3 (1997) 613-619
41. Agathos E.A., and Starr A. Mitral valve replacement. Curr Probl Surg 30 6 (1993) 481-592
42. Damle A., Coles J., Teijeira J., Pelletier C., and Callaghan J. A six-year study of the Omniscience valve in four Canadian centers. Ann Thorac Surg 43 5 (1987) 513-521
43. Torregrosa S., Gomez-Plana J., Valera F.J., Caffarena J., Maronas J.M., Garcia-Sanchez F., et al. Long-term clinical experience with the Omnicarbon prosthetic valve. Ann Thorac Surg 68 3 (1999) 881-886
44. Vallejo J.L., Gonzalez-Santos J.M., Albertos J., Riesgo M.J., Bastida M.E., Rico M.J., et al. Eight years' experience with the Medtronic-Hall valve prosthesis. Ann Thorac Surg 50 3 (1990) 429-436
45. Butchart E.G., Lewis P.A., Kulatilake E.N., and Breckenridge I.M. Anticoagulation variability between centres: implications for comparative prosthetic valve assessment. Eur J Cardiothorac Surg 2 2 (1988) 72-81
46. Cortina J.M., Martinell J., Artiz V., Fraile J., and Rabago G. Comparative clinical results with Omniscience (STM1), Medtronic-Hall, and Bjork-Shiley convexo-concave (70 degrees) prostheses in mitral valve replacement. J Thorac Cardiovasc Surg 91 2 (1986) 174-183
47. Akins C.W. Mechanical cardiac valvular prostheses. Ann Thorac Surg 52 1 (1991) 161-172
48. Gabbay S., McQueen D.M., Yellin E.L., Becker R.M., and Frater R.W. In vitro hydrodynamic comparison of mitral valve prostheses at high flow rates. J Thorac Cardiovasc Surg 76 6 (1978) 771-787
49. Chaux A., Gray R.J., Matloff J.M., Feldman H., and Sustaita H. An appreciation of the new St. Jude valvular prosthesis. J Thorac Cardiovasc Surg 81 2 (1981) 202-211
50. Arom K.V., Nicoloff D.M., Kersten T.E., Northrup III W.F., Lindsay W.G., and Emery R.W. Ten years' experience with the St. Jude Medical valve prosthesis. Ann Thorac Surg 47 6 (1989) 831-837
51. Czer L.S., Matloff J.M., Chaux A., De Robertis M., Stewart M.E., and Gray R.J. The St. Jude valve: analysis of thromboembolism, warfarin-related hemorrhage, and survival. Am Heart J 114 2 (1987) 389-397
52. Kopf G.S., Hammond G.L., Geha A.S., Elefteriades J., and Hashim S.W. Long-term performance of the St. Jude Medical valve: low incidence of thromboembolism and hemorrhagic complications with modest doses of warfarin. Circulation 76 3, Part 2 (1987) III132-III136
53. Nistal J.F., Hurle A., Revuelta J.M., and Gandarillas M. Clinical experience with the CarboMedics valve: early results with a new bileaflet mechanical prosthesis. J Thorac Cardiovasc Surg 112 1 (1996) 59-68
54. Aoyagi S., Oryoji A., Nishi Y., Tanaka K., Kosuga K., and Oishi K. Long-term results of valve replacement with the St. Jude Medical valve. J Thorac Cardiovasc Surg 108 6 (1994) 1021-1029
55. Copeland III J.G., and Sethi G.K. Four-year experience with the CarboMedics valve: the North American experience. North American team of clinical investigators for the CarboMedics prosthetic heart valve. Ann Thorac Surg 58 3 (1994) 630-637 (discussion 637-638)
56. Copeland III J.G. An international experience with the CarboMedics prosthetic heart valve. J Heart Valve Dis 4 1 (1995) 56-62
57. Emery R.W., Petersen R.J., Kersten T.E., Stokman P., Harris K.M., Knickelbine T., et al. The initial United States experience with the ATS mechanical cardiac valve prosthesis. Heart Surg Forum 4 4 (2001) 346-352 (discussion 352-343)
58. Westaby S., Van Nooten G., Sharif H., Pillai R., and Caes F. Valve replacement with the ATS open pivot bileaflet prosthesis. Eur J Cardiothorac Surg 10 8 (1996) 660-665
59. Laczkovics A., Heidt M., Oelert H., Laufer G., Greve H., Pomar J.L., et al. Early clinical experience with the On-X prosthetic heart valve. J Heart Valve Dis 10 1 (2001) 94-99
60. Mathiesen T., Benediktsdottir K., Johnsson H., Lindqvist M., and von Holst H. Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatment. Acta Neurol Scand 91 3 (1995) 208-214
61. Horstkotte D., Schulte H.D., Bircks W., and Strauer B.E. Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 107 4 (1994) 1136-1145
62. DiSesa V.J., Collins Jr. J.J., and Cohn L.H. Hematological complications with the St. Jude valve and reduced-dose Coumadin. Ann Thorac Surg 48 2 (1989) 280-283
63. Misawa Y., Hasegawa T., and Kato M. Clinical experience with the Omnicarbon prosthetic heart valve. J Thorac Cardiovasc Surg 105 1 (1993) 168-172
64. Otaki M., and Kitamura N. Six years' experience with the Omnicarbon valve prosthesis. Cardiovasc Surg 1 5 (1993) 594-598
65. Akalin H., Corapcioglu E.T., Ozyurda U., Ucanok K., Uysalel A., Kaya B., et al. Clinical evaluation of the Omniscience cardiac valve prosthesis. Follow-up of up to 6 years. J Thorac Cardiovasc Surg 103 2 (1992) 259-266
66. Butchart E.G., Li H.H., Payne N., Buchan K., and Grunkemeier G.L. Twenty years' experience with the Medtronic Hall valve. J Thorac Cardiovasc Surg 121 6 (2001) 1090-1100
67. de Luca L., Vitale N., Giannolo B., Cafarella G., Piazza L., and Cotrufo M. Mid-term follow-up after heart valve replacement with CarboMedics bileaflet prostheses. J Thorac Cardiovasc Surg 106 6 (1993) 1158-1165
68. Bhuvaneshwar G.S., Muraleedharan C.V., Vijayan G.A., Kumar R.S., and Valiathan M.S. Development of the Chitra tilting disc heart valve prosthesis. J Heart Valve Dis 5 4 (1996) 448-458
69. Sankarkumar R., Bhuvaneshwar G.S., Magotra R., Muralidharan S., Rajan R.S., Saha D., et al. Chitra heart valve: results of a multicenter clinical study. J Heart Valve Dis 10 5 (2001) 619-627
70. Rao S., Kurian V.M., Ghosh M., Sankarkumar R., Mohansingh M.P., and Valiathan M.S. Clinical course after mitral valve replacement. Indian Heart J 42 5 (1990) 335-339
71. Toker M.E., Eren E., Balkanay M., Kirali K., Yanartas M., Caliskan A., et al. Multivariate analysis for operative mortality in obstructive prosthetic valve dysfunction due to pannus and thrombus formation. Int Heart J 47 2 (2006) 237-245
72. Vitale N., Renzulli A., Agozzino L., Pollice A., Tedesco N., de Luca Tupputi Schinosa L., et al. Obstruction of mechanical mitral prostheses: analysis of pathologic findings. Ann Thorac Surg 63 4 (1997) 1101-1106
73. Girard S.E., Miller Jr. F.A., Orszulak T.A., Mullany C.J., Montgomery S., Edwards W.D., et al. Reoperation for prosthetic aortic valve obstruction in the era of echocardiography: trends in diagnostic testing and comparison with surgical findings. J Am Coll Cardiol 37 2 (2001) 579-584
74. Teshima H., Hayashida N., Yano H., Nishimi M., Tayama E., Fukunaga S., et al. Obstruction of St. Jude Medical valves in the aortic position: histology and immunohistochemistry of pannus. J Thorac Cardiovasc Surg 126 2 (2003) 401-407
75. Bonfield T., and Anderson J. Functional versus quantitative comparison of IL-1 beta from monocytes/macrophages on biomedical polymers [published erratum appears in J Biomed Mater Res 1994 Jan;28(1);137]. J Biomed Mater Res 27 9 (1993) 1195-1199
76. Jamieson W.R. Advanced technologies for cardiac valvular replacement, transcatheter innovations and reconstructive surgery. Surg Technol Int 15 (2006) 149-187
77. Williams M.A., Crause L., and Van Riet S. A comparison of mechanical valve performance in a poorly anticoagulated community. J Card Surg 19 5 (2004) 410-414
78. Horstkotte D., Hering D., Wiemer M., and Piper C. Discontinuing oral anticoagulation therapy. J Heart Valve Dis 16 3 (2007) 282-284
79. Walley V.M., and Keon W.J. Patterns of failure in Ionescu-Shiley bovine pericardial bioprosthetic valves. J Thorac Cardiovasc Surg 93 6 (1987) 925-933
80. Ius P., Thiene G., Minarini M., Valente M., Bortolotti U., Talenti E., et al. Low-profile porcine bioprosthesis (Liotta): pathologic findings and mode of failure in the long-term. J Heart Valve Dis 5 3 (1996) 323-327
81. Gott J., Girardot M., Girardot J., Hall J., Whitlark J., Horsley W., et al. Refinement of the alpha aminooleic acid bioprosthetic valve anticalcification technique. Ann Thorac Surg 64 1 (1997) 50-58
82. Ogle M., Kelly S., Bianco R., and Levy R. Calcification resistance with aluminum-ethanol treated porcine aortic valve bioprostheses in juvenile sheep. Ann Thorac Surg 75 4 (2003) 1267-1273
83. Isenburg J., Simionescu D., and Vyavahare N. Tannic acid treatment enhances biostability and reduces calcification of glutaraldehyde fixed aortic wall. Biomaterials 26 (2005) 1237-1245
84. Pettenazzo E., Valente M., and Thiene G. Toronto porcine stentless valve and the need for something more. Cardiovasc Pathol 15 1 (2006) 1-2
85. Melina G., Horkaew P., Amrani M., Rubens M.B., Yacoub M.H., and Yang G.Z. Three-dimensional in vivo characterization of calcification in native valves and in Freestyle versus homograft aortic valves. J Thorac Cardiovasc Surg 130 1 (2005) 41-47
86. Camilleri J., Pornin B., and Carpentier A. Structural changes of glutaraldehyde-treated porcine bioprosthetic valves. Arch Pathol Lab Med 106 10 (1982) 490-496
87. Schoen F., and Hobson C. Anatomic analysis of removed prosthetic heart valves: causes of failure of 33 mechanical valves and 58 bioprostheses, 1980 to 1983. Hum Pathol 16 6 (1985) 549-559
88. Human P., and Zilla P. Characterization of the immune response to valve bioprostheses and its role in primary tissue failure. Ann Thorac Surg 71 5, Suppl (2001) S385-S388
89. Nimni M., Cheung D., Strates B., Kodama M., and Sheikh K. Chemically modified collagen: a natural biomaterial for tissue replacement. J Biomed Mater Res 21 6 (1987) 741-771
90. Dahm M., Lyman W., Schwell A., Factor S., and Frater R. Immunogenicity of glutaraldehyde-tanned bovine pericardium. J Thorac Cardiovasc Surg 99 6 (1990) 1082-1090
91. Human P., and Zilla P. The possible role of immune responses in bioprosthetic heart valve failure. J Heart Valve Dis 10 4 (2001) 460-466
92. Vincentelli A., Latremouille C., Zegdi R., Shen M., Lajos P., Chachques J., et al. Does glutaraldehyde induce calcification of bioprosthetic tissues?. Ann Thorac Surg 66 6, Suppl (1998) S255-S258
93. Zilla P., Weissenstein C., Bracher M., Zhang Y., Koen W., Human P., et al. High glutaraldehyde concentrations reduce rather than increase the calcification of aortic wall tissue. J Heart Valve Dis 6 5 (1997) 502-509
94. Zilla P., Weissenstein C., Human P., Dower T., and von Oppell U. High glutaraldehyde concentrations mitigate bioprosthetic root calcification in the sheep model. Ann Thorac Surg 70 6 (2000) 2091-2095
95. Human P., and Zilla P. Graft-specific antibody implicated in calcification of valve bioprosthetic tissue. J Cardiovasc Path 9 4 (2000) 205
96. Human P., and Zilla P. Inflammatory and immune processes: the neglected villain of bioprosthetic degeneration?. J Long Term Eff Med Implants 11 4 (2001)
97. Ferrans V., Spray T., Billingham M., and Roberts W. Structural changes in glutaraldehyde-treated porcine heterografts used as substitute cardiac valves. Transmission and scanning electron microscopic observations in 12 patients. Am J Cardiol 41 7 (1978) 1159-1184
98. Schoen J., Shemin R., and Cohn L. Pathologic evaluation of a unileaflet pericardial bioprosthesis after implantation as tricuspid and mitral valve replacements in sheep. Trans Soc Biomater 9 (1986) 76
99. Trantina-Yates A., Weissenstein C., Human P., and Zilla P. Stentless bioprosthetic heart valve research: sheep versus primate model. Ann Thorac Surg 71 5, Suppl (2001) S422-S427
100. Nistal F., Garcia S.E., Artinano E., Duran C., and Gallo I. Comparative study of primary tissue valve failure between Ionescu-Shiley pericardial and Hancock porcine valves in the aortic position. Am J Cardiol 57 1 (1986) 161-164
101. Dahm M., Husmann M., Eckhard M., Prufer D., Groh E., and Oelert H. Relevance of immunologic reactions for tissue failure of bioprosthetic heart valves. Ann Thorac Surg 60 2, Suppl (1995) S348-S352
102. Valente M., Bortolotti U., and Thiene G. Ultrastructural substrates of dystrophic calcification in porcine bioprosthetic valve failure. Am J Pathol 119 1 (1985) 12-21
103. Everts V., van d.Z.E., Creemers L., and Beertsen W. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem J 28 4 (1996) 229-245
104. Stein P., Wang C., Riddle J., and Magilligan D.J. Leukocytes, platelets, and surface microstructure of spontaneously degenerated porcine bioprosthetic valves. J Card Surg 3 3 (1988) 253-261
105. Maxwell L., Gavin J., and Barratt-Boyes B. Uneven host tissue ongrowth and tissue detachment in stent mounted heart valve allografts and xenografts. Cardiovasc Res 23 8 (1989) 709-714
106. Thubrikar M., Bosher L., and Nolan S. The mechanism of opening of the aortic valve. J Thorac Cardiovasc Surg 77 6 (1979) 863-870
107. Golomb G., Schoen F., Smith M., Linden J., Dixon M., and Levy R. The role of glutaraldehyde-induced cross-links in calcification of bovine pericardium used in cardiac valve bioprostheses. Am J Pathol 127 1 (1987) 122-130
108. Zilla P., Fullard L., Trescony P., Meinhart J., Bezuidenhout D., Gorlitzer M., et al. Glutaraldehyde detoxification of aortic wall tissue: a promising perspective for emerging bioprosthetic valve concepts. J Heart Valve Dis 6 5 (1997) 510-520
109. Dewanjee M., Solis E., Lanker J., Mackey S., Lombardo G., Tidwell C., et al. Effect of diphosphonate binding to collagen upon inhibition of calcification and promotion of spontaneous endothelial cell coverage on tissue valve prostheses. ASAIO Trans 32 1 (1986) 24-29
110. Weissenstein C., Human P., Bezuidenhout D., and Zilla P. Glutaraldehyde detoxification in addition to enhanced amine cross-linking dramatically reduces bioprosthetic tissue calcification in the rat model. J Heart Valve Dis 9 2 (2000) 230-240
111. Grabenwoger M., Grimm M., Eybl E., Leukauf C., Muller M., Plenck H.J., et al. Decreased tissue reaction to bioprosthetic heart valve material after l-glutamic acid treatment. A morphological study. J Biomed Mater Res 26 9 (1992) 1231-1240
112. Zilla P., Bezuidenhout D., and Human P. Carbomiide treatment dramatically potentiates the anti-calcific effect of AOA on glutaraldehyde fixed aortic wall tissue. Ann Thorac Surg 79 (2005) 905-910
113. Schoen F. Pathologic findings in explanted clinical bioprosthetic valves fabricated from photooxidized bovine pericardium. J Heart Valve Dis 7 2 (1998) 174-179
114. Bianco R., Phillips R., Mrachek J., and Witson J. Feasibility evaluation of a new pericardial bioprosthesis with dye mediated photo-oxidized bovine pericardial tissue. J Heart Valve Dis 5 3 (1996) 317-322
115. Sung H., Hsu H., Shih C., and Lin D. Cross-linking characteristics of biological tissues fixed with monofunctional or multifunctional epoxy compounds. Biomaterials 17 14 (1996) 1405-1410
116. Olde Damink L., Dijkstra P., van L.M., van W.P., Nieuwenhuis P., and Feijen J. Cross-linking of dermal sheep collagen using a water-soluble carbodiimide. Biomaterials 17 8 (1996) 765-773
117. Zeeman R., Dijkstra P., van Wachem P., van Luyn M., Hendriks M., Cahalan P., et al. Crosslinking and modification of dermal sheep collagen using 1, 4-butanediol diglycidyl ether. J Biomed Mater Res 46 3 (1999) 424-433
118. Sung H., Chen C., Liang H., and Hong M. A natural compound (reuterin) produced by Lactobacillus reuteri for biological-tissue fixation. Biomaterials 24 8 (2003) 1335-1347
119. Sung H., Chang Y., Chiu C., Chen C., and Liang H. Mechanical properties of a porcine aortic valve fixed with a naturally occurring crosslinking agent. Biomaterials 20 19 (1999) 1759-1772
120. Hendriks M., Everaerts F., and Verhoeven M. Alternative fixation of bioprostheses. J Long Term Eff Med Implants 11 3 & 4 (2001) 163-183
121. Everaerts F., Torrianni M., Human P., Zilla P., van Wachem P., Brouwer L., et al. Abstract: variations in amine blockers successfully mitigates calcification of carbodiimide crosslinked tissue. Cardiovasc Pathol 11 1 (2002) 41
122. Everaerts F., Torrianni M., van L.M., van W.P., Feijen J., and Hendriks M. Reduced calcification of bioprostheses, cross-linked via an improved carbodiimide based method. Biomaterials 25 24 (2004) 5523-5530
123. Everaerts F, Torrianni M, Hendriks M, Feijen J. Biomechanical properties of carbodiimide cross-linked collagen: influence of the formation of ester cross-links. J Biomed Mater Res A 2007; (in press).
124. Rosenberg N., Henderson J., Douglas J., Lord G., and Gaughran E. Use of enzyme-digested heterografts as segmental arterial substitutes. III. Follow-up observations on two-year-old aortic implants. Arch Surg 76 (1958) 275
125. Simon P., Kasimir M.T., Seebacher G., Weigel G., Ullrich R., Salzer-Muhar U., et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg 23 6 (2003) 1002-1006 (discussion 1006)
126. Sayk F., Bos I., Schubert U., Wedel T., and Sievers H.H. Histopathologic findings in a novel decellularized pulmonary homograft: an autopsy study. Ann Thorac Surg 79 5 (2005) 1755-1758
127. Leyh R., Wilhelmi M., Rebe P., Fischer S., Kofidis T., Haverich A., et al. In vivo repopulation of xenogeneic and allogeneic acellular valve matrix conduits in the pulmonary circulation. Ann Thorac Surg 75 5 (2003) 1457-1463 (discussion 1463)
128. Dohmen P.M., Costa F., Lopes S.V., Yoshi S., Souza F.P., Vilani R., et al. Results of a decellularized porcine heart valve implanted into the juvenile sheep model. Heart Surg Forum 8 2 (2005) E100-E104 (discussion E104)
129. Affonso da Costa F.D., Dohmen P.M., Lopes S.V., Lacerda G., Pohl F., Vilani R., et al. Comparison of cryopreserved homografts and decellularized porcine heterografts implanted in sheep. Artif Organs 28 4 (2004) 366-370
130. Iwai S., Torikai K., Coppin C.M., and Sawa Y. Minimally immunogenic decellularized porcine valve provides in situ recellularization as a stentless bioprosthetic valve. J Artif Organs 10 1 (2007) 29-35
131. Rieder E., Nigisch A., Dekan B., Kasimir M.T., Muhlbacher F., Wolner E., et al. Granulocyte-based immune response against decellularized or glutaraldehyde cross-linked vascular tissue. Biomaterials 27 33 (2006) 5634-5642
132. Kasimir M.T., Rieder E., Seebacher G., Nigisch A., Dekan B., Wolner E., et al. Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J Heart Valve Dis 15 2 (2006) 278-286 (discussion 286)
133. Stock U.A., and Schenke-Layland K. Performance of decellularized xenogeneic tissue in heart valve replacement. Biomaterials 27 1 (2006) 1-2
134. Mitchell R.N., Jonas R.A., and Schoen F.J. Pathology of explanted cryopreserved allograft heart valves: comparison with aortic valves from orthotopic heart transplants. J Thorac Cardiovasc Surg 115 1 (1998) 118-127
135. Oosthuysen A., Zilla P.P., Human P.A., Schmidt C.A., and Bezuidenhout D. Bioprosthetic tissue preservation by filling with a poly(acrylamide) hydrogel. Biomaterials 27 9 (2006) 2123-2130
136. Roe B.B., Kelly Jr. P.B., Myers J.L., and Moore D.W. Tricuspid leaflet aortic valve prosthesis. Circulation 33 4, Suppl (1966) I124-I130
137. Sachweh J.S., and Daebritz S.H. Novel "biomechanical" polymeric valve prostheses with special design for aortic and mitral position: a future option for pediatric patients?. Asaio J 52 5 (2006) 575-580
138. Akutsu T., Dreyer B., and Kolff W.J. Polyurethane artificial heart valves in animals. J Appl Physiol 14 (1959) 1045-1048
139. Imamura E., Kaye M.P., and Davis G.D. Radiographic assessment of leaflet motion of Gore-Tex laminate trileaflet valves and Hancock xenograft in tricuspid position of dogs. Circulation 56 6 (1977) 1053-1058
140. Mohri H., Hessel E., Nelson R., Anderson H., Dillard D., and Merendino K. Design and durability test of silastic trileaflet aortic valve prosthesis. J Thorac Cardiovasc Surg 65 (1972) 576-582
141. Roe B.B., and Moore D. Design and fabrication of prosthetic valves. Exp Med Surg 16 2-3 (1958) 177-182
142. Wisman C.B., Pierce W.S., Donachy J.H., Pae W.E., Myers J.L., and Prophet G.A. A polyurethane trileaflet cardiac valve prosthesis: in vitro and in vivo studies. Trans Am Soc Artif Intern Organs 28 (1982) 164-168
143. Jansen J., Willeke S., Reiners B., Harbott P., Reul H., Lo H.B., et al. Advances in design principle and fluid dynamics of a flexible polymeric heart valve. ASAIO Trans 37 3 (1991) M451-M453
144. Jansen J., Willeke S., Reiners B., Harbott P., Reul H., and Rau G. New J-3 flexible-leaflet polyurethane heart valve prosthesis with improved hydrodynamic performance. Int J Artif Organs 14 10 (1991) 655-660
145. Leat M.E., and Fisher J. The influence of manufacturing methods on the function and performance of a synthetic leaflet heart valve. Proc Inst Mech Eng [H] 209 1 (1995) 65-69
146. Mackay T.G., Wheatley D.J., Bernacca G.M., Fisher A.C., and Hindle C.S. New polyurethane heart valve prosthesis: design, manufacture and evaluation. Biomaterials 17 19 (1996) 1857-1863
147. Butterfield M., Wheatley D.J., Williams D.F., and Fisher J. A new design for polyurethane heart valves. J Heart Valve Dis 10 1 (2001) 105-110
148. Daebritz S.H., Fausten B., Hermanns B., Franke A., Schroeder J., Groetzner J., et al. New flexible polymeric heart valve prostheses for the mitral and aortic positions. Heart Surg Forum 7 5 (2004) E525-E532
149. Hufnagel C.A. Reflections on the development of valvular prostheses. Med Instrum 11 2 (1977) 74-76
150. Daebritz S.H., Sachweh J.S., Hermanns B., Fausten B., Franke A., Groetzner J., et al. Introduction of a flexible polymeric heart valve prosthesis with special design for mitral position. Circulation 108 Suppl 1 (2003) II134-II139
151. Bernacca G.M., Mackay T.G., Wilkinson R., and Wheatley D.J. Polyurethane heart valves: fatigue failure, calcification, and polyurethane structure. J Biomed Mater Res 34 3 (1997) 371-379
152. Zdrahala R.J., and Zdrahala I.J. Biomedical applications of polyurethanes: a review of past promises, present realities, and a vibrant future. J Biomater Appl 14 1 (1999) 67-90
153. Simmons A., Hyvarinen J., Odell R.A., Martin D.J., Gunatillake P.A., Noble K.R., et al. Long-term in vivo biostability of poly(dimethylsiloxane)/poly(hexamethylene oxide) mixed macrodiol-based polyurethane elastomers. Biomaterials 25 20 (2004) 4887-4900
154. Uchiyama K., Fujisawa N., Shimazaki Y., Ranawake M., Fujimoto T., and Umezu M. Automated fabrication of polyurethane heart valves. Jpn J Artif Organs 23 (1994) 124-129
155. Bernacca G.M., Mackay T.G., Gulbransen M.J., Donn A.W., and Wheatley D.J. Polyurethane heart valve durability: effects of leaflet thickness and material. Int J Artif Organs 20 6 (1997) 327-331
156. Hyde J.A., Chinn J.A., and Phillips Jr. R.E. Polymer heart valves. J Heart Valve Dis 8 3 (1999) 331-339
157. Chetta G.E., and Lloyd J.R. The design, fabrication and evaluation of a trileaflet prosthetic heart valve. J Biomech Eng 102 1 (1980) 34-41
158. Braunwald N.S., and Morrow A.G. A late evaluation of flexible teflon prostheses utilized for total aortic valve replacement. Postoperative clinical, hemodynamic, and pathological assessments. J Thorac Cardiovasc Surg 49 (1965) 485-496
159. Nistal F., Garcia-Martinez V., Arbe E., Fernandez D., Artinano E., Mazorra F., et al. In vivo experimental assessment of polytetrafluoroethylene trileaflet heart valve prosthesis. J Thorac Cardiovasc Surg 99 6 (1990) 1074-1081
160. Gallocher S.L., Aguirre A.F., Kasyanov V., Pinchuk L., and Schoephoerster R.T. A novel polymer for potential use in a trileaflet heart valve. J Biomed Mater Res B Appl Biomater 79 2 (2006) 325-334
161. Yin W., Gallocher S., Pinchuk L., Schoephoerster R.T., Jesty J., and Bluestein D. Flow-induced platelet activation in a St. Jude Mechanical heart valve, a trileaflet polymeric heart valve, and a St. Jude tissue valve. Artif Organs 29 10 (2005) 826-831
162. Wheatley D.J., Raco L., Bernacca G.M., Sim I., Belcher P.R., and Boyd J.S. Polyurethane: material for the next generation of heart valve prostheses?. Eur J Cardiothorac Surg 17 4 (2000) 440-448
163. Roe B.B., Owsley J.W., and Boudoures P.C. Experimental results with a prosthetic aortic valve. J Thorac Surg 36 4 (1958) 563-570
164. Hilbert S.L., Ferrans V.J., Tomita Y., Eidbo E.E., and Jones M. Evaluation of explanted polyurethane trileaflet cardiac valve prostheses. J Thorac Cardiovasc Surg 94 3 (1987) 419-429
165. Kolff W.J., and Yu L.S. The return of elastomer valves. Ann Thorac Surg 48 3, Suppl (1989) S98-S99
166. Lo H.B., Herold M., Reul H., Muckter H., Taguchi K., Surmann M., et al. A tricuspid polyurethane heart valve as an alternative to mechanical prostheses or bioprostheses. ASAIO Trans 34 3 (1988) 839-844
167. Bernacca G.M., Mackay T.G., Wilkinson R., and Wheatley D.J. Calcification and fatigue failure in a polyurethane heart value. Biomaterials 16 4 (1995) 279-285
168. Joshi R.R., Frautschi J.R., Phillips Jr. R.E., and Levy R.J. Phosphonated polyurethanes that resist calcification. J Appl Biomater 5 1 (1994) 65-77
169. Alferiev I., Vyavahare N., Song C., Connolly J., Hinson J.T., Lu Z., et al. Bisphosphonate derivatized polyurethanes resist calcification. Biomaterials 22 19 (2001) 2683-2693
170. Han D.K., Park K., Park K.D., Ahn K.D., and Kim Y.H. In vivo biocompatibility of sulfonated PEO-grafted polyurethanes for polymer heart valve and vascular graft. Artif Organs 30 12 (2006) 955-959
171. Bernacca G.M., and Wheatley D.J. Surface modification of polyurethane heart valves: effects on fatigue life and calcification. Int J Artif Organs 21 12 (1998) 814-819
172. Fasol R., Zilla P., Deutsch M., Fischlein T., Kadletz M., Griesmacher A., et al. Endothelialization of artificial surfaces: does surface tension determine in vitro growth of human saphenous vein endothelial cells?. Tex Heart Inst J 14 2 (1987) 119-126
173. Fasol R., Zilla P., Groscurth P., Wolner E., and Moser R. Experimental in vitro cultivation of human endothelial cells on artificial surfaces. Trans Am Soc Artif Intern Organs 31 (1985) 276-283
174. Zilla P., Fasol R., Grimm M., Fischlein T., Eberl T., Preiss P., et al. Growth properties of cultured human endothelial cells on differently coated artificial heart materials. J Thorac Cardiovasc Surg 101 4 (1991) 671-680
175. Stachelek S.J., Alferiev I., Choi H., Kronsteiner A., Uttayarat P., Gooch K.J., et al. Cholesterol-derivatized polyurethane: characterization and endothelial cell adhesion. J Biomed Mater Res A 72 2 (2005) 200-212
176. Stachelek S.J., Alferiev I., Connolly J.M., Sacks M., Hebbel R.P., Bianco R., et al. Cholesterol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial cell adhesion post-seeding in vitro and in vivo. Ann Thorac Surg 81 1 (2006) 47-55
177. Shi Q., Wu M., Hayashida N., Wechezak A., Clowes A., and Sauvage L. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog. J Vasc Surg 20 4 (1994) 546-556 (discussion 556-547)
178. Cebotari S., Lichtenberg A., Tudorache I., Hilfiker A., Mertsching H., Leyh R., et al. Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 114 1, Suppl (2006) I132-I137
179. Hoerstrup S.P., Cummings Mrcs I., Lachat M., Schoen F.J., Jenni R., Leschka S., et al. Functional growth in tissue-engineered living, vascular grafts: follow-up at 100 weeks in a large animal model. Circulation 114 1, Suppl (2006) I159-I166
180. Mol A., Rutten M.C., Driessen N.J., Bouten C.V., Zund G., Baaijens F.P., et al. Autologous human tissue-engineered heart valves: prospects for systemic application. Circulation 114 1, Suppl (2006) I152-I158
181. Hoerstrup S.P., Sodian R., Daebritz S., Wang J., Bacha E.A., Martin D.P., et al. Functional living trileaflet heart valves grown in vitro. Circulation 102 19, Suppl 3 (2000) III44-III49
182. Shinoka T., Breuer C., Tanel R., Zund G., Miura T., Ma P., et al. Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann Thorac Surg 60 6, Suppl (1995) S513-S516
183. Shinoka T., Ma P., Shum - T.D., Breuer C., Cusick R., Zund G., et al. Tissue-engineered heart valves. Autologous valve leaflet replacement study in a lamb model. Circulation 94 9, Suppl (1996) II164-II168
184. Mendelson K., and Schoen F.J. Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann Biomed Eng 34 12 (2006) 1799-1819
185. Rafii S., Oz M.C., Seldomridge J.A., Ferris B., Asch A.S., Nachman R.L., et al. Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices. Ann Thorac Surg 60 6 (1995) 1627-1632
186. Frazier O.H., Baldwin R.T., Eskin S.G., and Duncan J.M. Immunochemical identification of human endothelial cells on the lining of a ventricular assist device. Tex Heart Inst J 20 2 (1993) 78-82
187. Aoki J., Serruys P.W., van Beusekom H., Ong A.T., McFadden E.P., Sianos G., et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 45 10 (2005) 1574-1579
188. Schmidt D., Mol A., Breymann C., Achermann J., Odermatt B., Gossi M., et al. Living autologous heart valves engineered from human prenatally harvested progenitors. Circulation 114 1, Suppl (2006) I125-I131
189. Pavcnik D., Wright K.C., and Wallace S. Development and initial experimental evaluation of a prosthetic aortic valve for transcatheter placement. Work in progress. Radiology 183 1 (1992) 151-154
190. Sochman J., Peregrin J.H., Pavcnik D., Timmermans H., and Rosch J. Percutaneous transcatheter aortic disc valve prosthesis implantation: a feasibility study. Cardiovasc Intervent Radiol 23 5 (2000) 384-388
191. Walther T., and Mohr F.W. Aortic valve surgery: time to be open-minded and to rethink. Eur J Cardiothorac Surg 31 1 (2007) 4-6
192. Antunes M.J. Off-pump aortic valve replacement with catheter-mounted valved stents. Is the future already here?. Eur J Cardiothorac Surg 31 1 (2007) 1-3
193. Davidson M.J., White J.K., and Baim D.S. Percutaneous therapies for valvular heart disease. Cardiovasc Pathol 15 3 (2006) 123-129
194. Andersen H.R., Knudsen L.L., and Hasenkam J.M. Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. Eur Heart J 13 5 (1992) 704-708
195. Bonhoeffer P., Boudjemline Y., Saliba Z., Merckx J., Aggoun Y., Bonnet D., et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 356 9239 (2000) 1403-1405
196. Cribier A., Eltchaninoff H., Bash A., Borenstein N., Tron C., Bauer F., et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106 24 (2002) 3006-3008
197. Bonhoeffer P. Pioneers in cardiology. An interview with Philipp Bonhoeffer by Robert Short. Circulation 113 24 (2006) f94-f95
198. Cribier A., Eltchaninoff H., Tron C., Bauer F., Agatiello C., Nercolini D., et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. J Am Coll Cardiol 47 6 (2006) 1214-1223
199. Grube E., Laborde J.C., Gerckens U., Felderhoff T., Sauren B., Buellesfeld L., et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 114 15 (2006) 1616-1624
200. Grube E., Laborde J.C., Zickmann B., Gerckens U., Felderhoff T., Sauren B., et al. First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. Catheter Cardiovasc Interv 66 4 (2005) 465-469
201. Nordmeyer J., Coats L., and Bonhoeffer P. Current experience with percutaneous pulmonary valve implantation. Semin Thorac Cardiovasc Surg 18 2 (2006) 122-125
202. Webb J.G., Chandavimol M., Thompson C.R., Ricci D.R., Carere R.G., Munt B.I., et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 113 6 (2006) 842-850
203. Ye J., Cheung A., Lichtenstein S.V., Pasupati S., Carere R.G., Thompson C.R., et al. Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients. Eur J Cardiothorac Surg 31 1 (2007) 16-21
204. Walther T., Falk V., Borger M.A., Dewey T., Wimmer-Greinecker G., Schuler G., et al. Minimally invasive transapical beating heart aortic valve implantation-proof of concept. Eur J Cardiothorac Surg 31 1 (2007) 9-15
205. Schreiber C., Horer J., Vogt M., Fratz S., Kunze M., Galm C., et al. A new treatment option for pulmonary valvar insufficiency: first experiences with implantation of a self-expanding stented valve without use of cardiopulmonary bypass. Eur J Cardiothorac Surg 31 1 (2007) 26-30
206. Lichtenstein S.V. Closed heart surgery: back to the future. J Thorac Cardiovasc Surg 131 5 (2006) 941-943
207. Paniagua D., Condado J.A., Besso J., Velez M., Burger B., Bibbo S., et al. First human case of retrograde transcatheter implantation of an aortic valve prosthesis. Tex Heart Inst J 32 3 (2005) 393-398
208. Boudjemline Y., Pineau E., Borenstein N., Behr L., and Bonhoeffer P. New insights in minimally invasive valve replacement: description of a cooperative approach for the off-pump replacement of mitral valves. Eur Heart J 26 19 (2005) 2013-2017
209. Ma L., Tozzi P., Huber C.H., Taub S., Gerelle G., and von Segesser L.K. Double-crowned valved stents for off-pump mitral valve replacement. Eur J Cardiothorac Surg 28 2 (2005) 194-198 (discussion 198-199)
210. Huber C.H., and von Segesser L.K. Direct access valve replacement (DAVR)-are we entering a new era in cardiac surgery?. Eur J Cardiothorac Surg 29 3 (2006) 380-385
211. Walther T., Dewey T., Wimmer-Greinecker G., Doss M., Hambrecht R., Schuler G., et al. Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results. Eur J Cardiothorac Surg 29 5 (2006) 703-708
212. Vesely I, inventor. Bioprosthetic Cardiovascular Valve System, 2006.
213. Valencia HF, Hildebrand D, Krolik J, Geshlider RA, Saul T, Argento C, et al., inventors. Repositionable heart valve, CA, 2004.
214. Tozzi P., Pawelec-Wojtalic M., Bukowska D., Argitis V., and von Segesser L.K. Endoscopic off-pump aortic valve replacement: does the pericardial cuff improve the sutureless closure of left ventricular access?. Eur J Cardiothorac Surg 31 1 (2007) 22-25
215. Sochman J., Peregrin J.H., Rocek M., Timmermans H.A., Pavcnik D., and Rosch J. Percutaneous transcatheter one-step mechanical aortic disc valve prosthesis implantation: a preliminary feasibility study in swine. Cardiovasc Intervent Radiol 29 1 (2006) 114-119
216. Attmann T., Steinseifer U., Cremer J., and Lutter G. Percutaneous valve replacement: a novel low-profile polyurethane valved stent. Eur J Cardiothorac Surg 30 2 (2006) 379
217. Aikawa E., Nahrendorf M., Sosnovik D., Lok V.M., Jaffer F.A., Aikawa M., et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115 3 (2007) 377-386
218. Schmidt D., Mol A., Odermatt B., Neuenschwander S., Breymann C., Gossi M., et al. Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. Tissue Eng 12 11 (2006) 3223-3232
219. Schmidt D., Acherman J., Odermatt B., Breymann C., Mol A., Genoni M., et al. Prenatally fabricated autologous human living heart valves based on amniotic fluid-derived progenitor cells as single cell source. Circulation 116 Supp I (2007) 164-170